THALES
7.1.2020 14:42:11 CET | Business Wire | Press release
Thales has signed a contract to partner with Queensland’s Department of Transport and Main Roads (TMR) in Australia and local Queensland SMEs, Code Heroes and Aliva, to design, develop and deliver the State’s first Digital Licence App.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005628/en/
Thales worked closely with TMR and their customers to co-design a fully integrated app-based solution that is able to manage multiple digital credentials from various sources. The comprehensive solution that integrates a backend platform with managed services, builds upon Gemalto’s next generation Digital ID Platform and Wallet technology, a globally proven and secure, smartphone-based home for all of the owner's digital identity credentials.
Thales completed the acquisition of Gemalto in April 2019 during the TMR procurement process, acquiring a set of highly complementary technologies and competencies, and reinforcing Thales’s status as a world-leader in digital identity and security.
The all-in-one Digital Licence solution utilises a privacy enhanced app that acts as a secure digital vault to store a wide range of digitalized official documents, starting with the owner’s Driver’s Licence, Photo Identification Card, Marine Licence and vehicle registration. The innovative solution delivers ease of access via a smartphone, while ensuring the owner has complete control over their personal data and the freedom to decide exactly what information to share, with whom, and when.
The app will also provide Queenslanders with a secure gateway to access TMR’s online services, supporting the opportunity to expand to other State Government online services in the future.
The innovative solution will be piloted in the Fraser Coast in early 2020, before extending to other regional locations and becoming available to over 3.7 million Queenslanders state-wide.
A first for Australia, Queensland’s Digital Licence will meet the International ISO-Compliant Mobile Driving Licence Standard, allowing the State’s digital driver’s licences to be recognised and used in over 18 countries world-wide including the US, UK and France.
Thales Australia CEO, Chris Jenkins said
“We are excited to be partnering with the Queensland Government to deliver our secure Digital ID Wallet solution. This is the first major contract award in Australia that has resulted from the merger of Thales and Gemalto. The bringing together of two technology powerhouses has strengthened Thales’s position as a world leader in digital security. The Queensland Digital Licence end-to-end solution contract is a demonstration of the success of the integration.”
Note to Editors
Gemalto's solutions are at the heart of modern life, from payments to enterprise security and the internet of things. They authenticate people, transactions and objects, encrypt data and create value for software - enabling companies and governments to deliver secure digital services for billions of individuals and things.
About Thales
The people who make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary, high-technology solutions. Solutions that make tomorrow possible today. From the bottom of the oceans to the depths of space and cyberspace, we help our customers think smarter and act faster – mastering ever greater complexity at every decisive moment along the way.
Thales generated revenues of €19 billion in 2018 with 80 thousand employees in 68 countries.
PLEASE VISIT
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005628/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom